{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:37:04Z","timestamp":1772840224669,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ferring"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-018-3109-2","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T12:37:52Z","timestamp":1546519072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intramuscular oxytocin versus oxytocin\/ergometrine versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: study protocol for a randomised controlled trial (the IMox study)"],"prefix":"10.1186","volume":"20","author":[{"given":"Helen","family":"van der Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-8920","authenticated-orcid":false,"given":"Stephen","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Lenguerrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Burnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Siassakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Draycott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"3109_CR1","doi-asserted-by":"crossref","unstructured":"Say L, Chou D, Gemmill A, Tun\u00e7alp \u00d6, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014;2(6):e323\u201333.","DOI":"10.1016\/S2214-109X(14)70227-X"},{"issue":"4","key":"3109_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1479-828X.2011.01317.x","volume":"51","author":"JF Thompson","year":"2011","unstructured":"Thompson JF, Roberts CL, Ellwood DA. Emotional and physical health outcomes after significant primary post-partum haemorrhage (PPH): a multicentre cohort study. Aust N Z J Obstet Gynaecol. 2011;51(4):365\u201371.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"3109_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/GRF.0b013e3181cc406d","volume":"53","author":"Y Oyelese","year":"2010","unstructured":"Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol. 2010;53(1):147\u201356.","journal-title":"Clin Obstet Gynecol"},{"key":"3109_CR4","first-page":"CD007412","volume":"3","author":"CM Begley","year":"2015","unstructured":"Begley CM, Gyte GML, Devane D, McGuire W, Weeks A. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2015;3:CD007412.","journal-title":"Cochrane Database Syst Rev"},{"key":"3109_CR5","volume-title":"WHO recommendations for the prevention and treatment of postpartum haemorrhage","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: WHO; 2012."},{"issue":"5","key":"3109_CR6","first-page":"e106","volume":"124","author":"RCOG","year":"2016","unstructured":"RCOG. Prevention and Management of Postpartum Haemorrhage. BJOG. 2016;124(5):e106\u201349.","journal-title":"BJOG"},{"key":"3109_CR7","volume-title":"Intrapartum care: care of healthy women and their babies during hildbirth","author":"National Collaborating Centre for Women's and Children's Health (UK)","year":"2014","unstructured":"National Collaborating Centre for Women's and Children's Health (UK). Intrapartum care: care of healthy women and their babies during hildbirth. London: National Institute for Health and Care Excellence (UK); 2014."},{"issue":"2\u20133","key":"3109_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0014-2999(98)00513-5","volume":"355","author":"T Engstr\u00f8m","year":"1998","unstructured":"Engstr\u00f8m T, Barth T, Melin P, Vilhardt H. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998;355(2\u20133):203\u201310.","journal-title":"Eur J Pharmacol"},{"key":"3109_CR9","first-page":"CD011689","volume":"4","author":"ID Gallos","year":"2018","unstructured":"Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2018;4:CD011689.","journal-title":"Cochrane Database Syst Rev"},{"key":"3109_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1805489","volume":"379","author":"M Widmer","year":"2018","unstructured":"Widmer M, Piaggio G, Nguyen TMH, Osoti A, Owa OO, Misra S, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379:743\u201352 NEJMoa1805489.","journal-title":"N Engl J Med"},{"key":"3109_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1542-2011.2004.tb04420.x","volume":"49","author":"International Confederation of Midwives, International Federation of Gynaecologists and Obstetricians","year":"2004","unstructured":"International Confederation of Midwives, International Federation of Gynaecologists and Obstetricians. Joint statement: management of the third stage of labour to prevent post-partum haemorrhage. J Midwifery Womens Health. 2004;49:76\u20137.","journal-title":"J Midwifery Womens Health"},{"key":"3109_CR12","first-page":"38","volume-title":"Carbetocin for preventing postpartum haemorrhage. Su L-L, editor. Vol. 284","author":"L-L Su","year":"1996","unstructured":"Su L-L, Chong Y-S, Samuel M. Carbetocin for preventing postpartum haemorrhage. Su L-L, editor. Vol. 284. Chichester: John Wiley & Sons, Ltd; 1996. p. 38."},{"issue":"2","key":"3109_CR13","first-page":"119","volume":"38","author":"SJ Duthie","year":"1991","unstructured":"Duthie SJ, Ven D, Yung GL, Guang DZ, Chan SY, Ma HK. Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. EJOG. 1991;38(2):119\u201324.","journal-title":"EJOG"},{"issue":"8","key":"3109_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1471-0528.2006.01018.x","volume":"113","author":"P Bose","year":"2006","unstructured":"Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG. 2006;113(8):919\u201324.","journal-title":"BJOG"},{"key":"3109_CR15","first-page":"1","volume-title":"Guideline on multiplicity issues in clinical trials - for publication","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Guideline on multiplicity issues in clinical trials - for publication. London: European Medicines Agency; 2017. p. 1\u201315."},{"issue":"15","key":"3109_CR16","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/(SICI)1097-0258(19990815)18:15<1903::AID-SIM188>3.0.CO;2-F","volume":"18","author":"JA Lewis","year":"1999","unstructured":"Lewis JA. Consensus Guideline E9 (Statistical Principles for Clinical Trials). Stat Med. 1999;18(15):1903\u201342.","journal-title":"Stat Med"},{"key":"3109_CR17","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c332\u20132.","DOI":"10.1136\/bmj.c332"},{"key":"3109_CR18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/sim.2584","volume":"25","author":"Committee for Medicinal Products for Human Use","year":"2006","unstructured":"Committee for Medicinal Products for Human Use. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med. 2006;25:1628\u201338.","journal-title":"Stat Med"},{"key":"3109_CR19","first-page":"1","volume-title":"National Institute for Health and Care Excellence position statement on use of the EQ-5D-5L value set","author":"EuroQol","year":"2017","unstructured":"EuroQol. National Institute for Health and Care Excellence position statement on use of the EQ-5D-5L value set. Rotterdam: EuroQol; 2017. p. 1\u20133."},{"issue":"5","key":"3109_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","volume":"14","author":"A Manca","year":"2005","unstructured":"Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487\u201396.","journal-title":"Health Econ"},{"issue":"3","key":"3109_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3109_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/1471-0528.15335","volume":"126","author":"S Meher","year":"2019","unstructured":"Meher S, Cuthbert A, Kirkham JJ, Williamson P, Abalos E, Aflaifel N, et al. Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG. 2019;126(1):83\u201393.","journal-title":"BJOG"},{"issue":"1","key":"3109_CR23","first-page":"173","volume":"109","author":"SJ McDonald","year":"2004","unstructured":"McDonald SJ. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Pregnancy and Childbirth Group, editor. Cochrane Database Syst Rev. 2004;109(1):173\u201352.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3109-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3109-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3109-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:24:13Z","timestamp":1589995453000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3109-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3109"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3109-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The IMox study has been approved by the South Central \u2013 Oxford B Research Ethics Committee, UK on 28 October 2014, reference number 14\/SC\/1312, the Medicines and Healthcare products Regulatory Agency on 30 October 2014 and the Health Research Authority on 3 August 2016. Written consent has been gained antenatally from all trial participants. Consent may be withdrawn at any time without a reason being stated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TD has acted as a consultant for Ferring Pharmaceuticals Ltd. DS has received sponsorship to attend two conferences from Ferring Pharmaceuticals Ltd. and is a member of their GLOBE Personal Development Scheme. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"4"}}